Biovail Sues FDA Over Wellbutrin XL Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Company wants one week notice before agency approves generic to prepare suit.
You may also be interested in...
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
Federal Court Ruling Clears Way For Wellbutrin XL Generic
Judge declines to block FDA from approving generic version of GSK/Biovail’s bupropion extended-release.